Synageva Biopharma Corp Company Profile (NASDAQ:GEVA)

About Synageva Biopharma Corp (NASDAQ:GEVA)

Synageva Biopharma Corp logoSynageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GEVA
  • CUSIP: 87159A10
  • Web:
Average Prices:
  • 50 Day Moving Avg: $215.15
  • 200 Day Moving Avg: $131.31
  • 52 Week Range: $60.19 - $239.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -36.04
  • P/E Growth: 0.00
  • Net Margins: -6,429.45%
  • Return on Equity: -39.57%
  • Return on Assets: -37.57%
  • Average Volume: 895,402 shs.
Frequently Asked Questions for Synageva Biopharma Corp (NASDAQ:GEVA)

What is Synageva Biopharma Corp's stock symbol?

Synageva Biopharma Corp trades on the NASDAQ under the ticker symbol "GEVA."

How were Synageva Biopharma Corp's earnings last quarter?

Synageva Biopharma Corp (NASDAQ:GEVA) posted its earnings results on Thursday, February, 26th. The company reported ($1.73) earnings per share for the quarter, missing analysts' consensus estimates of ($1.71) by $0.02. The business earned $1.24 million during the quarter, compared to the consensus estimate of $1.25 million. Synageva Biopharma Corp had a negative return on equity of 39.57% and a negative net margin of 6,429.45%. View Synageva Biopharma Corp's Earnings History.

Who are some of Synageva Biopharma Corp's key competitors?

How do I buy Synageva Biopharma Corp stock?

Shares of Synageva Biopharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synageva Biopharma Corp's stock price today?

One share of Synageva Biopharma Corp stock can currently be purchased for approximately $238.60.

MarketBeat Community Rating for Synageva Biopharma Corp (NASDAQ GEVA)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Synageva Biopharma Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Synageva Biopharma Corp (NASDAQ:GEVA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Synageva Biopharma Corp (NASDAQ:GEVA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016WedbushBoost Price TargetNeutral$67.00 -> $93.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for Synageva Biopharma Corp (NASDAQ:GEVA)
Earnings by Quarter for Synageva Biopharma Corp (NASDAQ:GEVA)
Earnings History by Quarter for Synageva Biopharma Corp (NASDAQ GEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2015Q114($1.71)($1.73)$1.25 million$1.24 millionViewListenView Earnings Details
10/30/2014Q3 2014($1.61)($1.46)$1.40 million$1.33 millionViewN/AView Earnings Details
7/30/2014Q2 2014($1.37)($1.52)$1.43 million$2.34 millionViewN/AView Earnings Details
4/30/2014Q1 2014($1.19)($1.16)$1.86 million$1.59 millionViewN/AView Earnings Details
3/3/2014Q4 13($1.02)($1.00)$4.88 million$3.47 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.76)($0.81)$2.90 million$3.41 millionViewN/AView Earnings Details
3/11/2013Q4 2012($0.60)($0.62)$2.32 million$2.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Synageva Biopharma Corp (NASDAQ:GEVA)
Current Year EPS Consensus Estimate: $-7.33 EPS
Next Year EPS Consensus Estimate: $-6.62 EPS


Dividend History for Synageva Biopharma Corp (NASDAQ:GEVA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Synageva Biopharma Corp (NASDAQ:GEVA)
Insider Trades by Quarter for Synageva Biopharma Corp (NASDAQ:GEVA)
Insider Trades by Quarter for Synageva Biopharma Corp (NASDAQ:GEVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/8/2015Glen WilliamsSVPSell12,916$214.92$2,775,906.72View SEC Filing  
4/27/2015Anthony QuinnCMOSell10,000$110.00$1,100,000.00View SEC Filing  
4/21/2015Anthony QuinnCMOSell10,000$108.00$1,080,000.00View SEC Filing  
4/15/2015Anthony QuinnCMOSell10,000$105.00$1,050,000.00View SEC Filing  
4/8/2015Glen WilliamsSVPSell42,632$96.08$4,096,082.56View SEC Filing  
4/6/2015Anthony QuinnCMOSell29,503$93.76$2,766,201.28View SEC Filing  
1/7/2015Julian BakerDirectorBuy1,000,000$94.19$94,190,000.00View SEC Filing  
12/29/2014Chris HeberligVPSell6,100$91.14$555,954.00View SEC Filing  
12/17/2014Sanj K PatelCEOSell50,000$88.85$4,442,500.00View SEC Filing  
10/30/2014Carsten BoessCFOSell25,404$80.10$2,034,860.40View SEC Filing  
9/19/2014Mark Alan GoldbergEVPSell790$65.24$51,539.60View SEC Filing  
9/17/2014Mark Alan GoldbergEVPSell13,579$65.03$883,042.37View SEC Filing  
9/2/2014Anthony QuinnCMOSell10,000$70.14$701,400.00View SEC Filing  
6/20/2014Barry D QuartDirectorSell1,375$100.00$137,500.00View SEC Filing  
6/17/2014Barry D QuartDirectorSell1,000$90.00$90,000.00View SEC Filing  
6/12/2014Barry D QuartDirectorSell1,000$83.31$83,310.00View SEC Filing  
6/11/2014Mark Alan GoldbergEVPSell21,597$80.00$1,727,760.00View SEC Filing  
5/16/2014Carsten BoessCFOSell9,927$81.94$813,418.38View SEC Filing  
4/1/2014Anthony QuinnCMOSell20,000$83.53$1,670,600.00View SEC Filing  
3/12/2014Chris HeberligVPSell7,670$98.56$755,955.20View SEC Filing  
3/6/2014Felix BakerDirectorBuy375,000$105.75$39,656,250.00View SEC Filing  
1/29/2014Sanj PatelCEOSell102,300$88.12$9,014,676.00View SEC Filing  
12/3/2013Mark Alan GoldbergSVPSell7,000$60.52$423,640.00View SEC Filing  
11/1/2013Mark Alan GoldbergSVPSell7,000$49.96$349,720.00View SEC Filing  
9/25/2013Julian BakerDirectorBuy1,050,000$56.63$59,461,500.00View SEC Filing  
8/21/2013Carsten BoessCFOSell14,481$47.11$682,199.91View SEC Filing  
8/16/2013Carsten BoessCFOSell4,300$47.47$204,121.00View SEC Filing  
7/29/2013Sanj K PatelCEOSell100,000$48.02$4,802,000.00View SEC Filing  
7/16/2013Chris HeberligVPSell2,524$48.43$122,237.32View SEC Filing  
7/11/2013Carsten BoessCFOSell13,237$47.06$622,933.22View SEC Filing  
6/12/2013Sanj K PatelCEOSell70,000$40.65$2,845,500.00View SEC Filing  
2/1/2013Mark Alan GoldbergSVPSell4,417$47.75$210,911.75View SEC Filing  
1/17/2013Anthony QuinnSVPSell5,553$50.07$278,038.71View SEC Filing  
1/16/2013Carsten BoessCFOSell9,927$49.12$487,614.24View SEC Filing  
1/9/2013Thomas J TischDirectorBuy21,039$47.53$999,983.67View SEC Filing  
1/4/2013Julian BakerDirectorBuy859,720$47.53$40,862,491.60View SEC Filing  
9/4/2012Chris HeberligVPSell1,000$49.10$49,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Synageva Biopharma Corp (NASDAQ:GEVA)
Latest Headlines for Synageva Biopharma Corp (NASDAQ:GEVA)
DateHeadline logoSyros Pharmaceuticals (SYRS) Names Srinivas Akkaraju to Board - June 12 at 6:14 PM logoTake Advantage Of Donald Trump's Tweets To Buy Top Biotechs - March 25 at 10:14 AM logoAlexion Pharma's Bloated Blockbuster Deal Still Haunts - February 16 at 5:19 PM logoForm 8-K AVEO PHARMACEUTICALS For: Mar 17 - - March 22 at 1:18 PM logoOpinion: 4 beaten-down Internet companies that are takeover targets - MarketWatch - March 17 at 9:37 PM logoAeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of ... - Business Wire (press release) - March 15 at 7:40 PM logoKey Executives for Synageva BioPharma Corp. - February 18 at 6:13 PM logoSynageva Biopharma Corp. Company Profile - February 18 at 6:13 PM logoGeorgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration - Business Wire (press release) - January 22 at 4:48 PM logoFDA Accepts BLA Filing For Synageva's Kanuma™ (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date - January 17 at 4:41 PM logoAlexion gets EU approval for drug acquired in Synageva deal - September 1 at 3:29 PM logoSYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting o - June 23 at 8:17 AM logoAlexion Completes Acquisition of Synageva - June 23 at 6:30 AM logoGEVA helped advance Sectoral Asset 9.4% in May. ALXN did not - June 17 at 10:19 AM logo5 Healthy Stocks in the Top Biotech ETF - ETF News And Commentary - June 17 at 8:30 AM logoThe Only Way to Play Biotech Buyouts - June 9 at 9:46 AM logoSynageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB - June 4 at 4:05 PM logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp. - June 2 at 7:29 PM



Synageva Biopharma Corp (GEVA) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff